Results 81 to 90 of about 11,837 (160)

Ceftazidime-avibactam/aztreonam combination synergy against carbapenem-resistant Gram-negative isolates: In vitro study

Current Medicine Research and Practice
Background: The ceftazidime-avibactam combination is able to inhibit ESBLs, AmpCs and Class A carbapenemases and has been recommended for the treatment of complicated UTIs and ventilator-associated bacterial pneumonia.
Reena Rajan, A V Raghavendra Rao, Mathavi Suresh Kumar   +2 more
doaj   +1 more source

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

Infection and Drug Resistance, 2018
Stan D Atkin,1 Shadaan Abid,1 Michael Foster,1 Moumita Bose,1 Ashley Keller,1 Rita Hollaway,2 Helio S Sader,3 David E Greenberg,1,4 James D Finklea,1 Mariana Castanheira,3 Raksha Jain1,4 1Department of Internal Medicine, University of Texas Southwestern ...
Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M, Jain R   +10 more
doaj  

In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex

PLoS ONE
Background Infections caused by Stenotrophomonas maltophilia and related species are increasing worldwide. Unfortunately, treatment options are limited, whereas the antimicrobial resistance is increasing.
B. Méndez-Sotelo, Mónica Delgado-Beltrán, Melissa Hernández-Durán, C. Colín-Castro, José Esquivel-Bautista, Sandra Angélica Ortega-Oliva, Jossué Ortíz-Álvarez, Rodolfo García-Contreras, R. Franco-Cendejas, Luis Esau López Jacome   +9 more
semanticscholar   +1 more source

Experience with ceftazidime–avibactam treatment in a tertiary care center in Saudi Arabia

Journal of Infection and Public Health, 2018
Introduction: Carbapenem-resistant organisms have become major healthcare-associated pathogens and are responsible for significant morbidity and mortality worldwide.
Abdullah Algwizani, Mohammad Alzunitan, Ahmad Alharbi, Abdulrahman Alsaedy, Sameera Aljohani, Bassam Alalwan, Jawaher Gramish, Adel Alothman   +7 more
doaj   +1 more source

Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy.

Indian Journal of Medical Microbiology
PURPOSE The choice of antibiotics for treatment of Carbapenem-Resistant Enterobacterales (CRE) is increasing becoming limited due to co-expression of Metallo-beta-lactamases (MBL) along with other carbapenemases in these isolates.
R. Kalaivani, A. Kali, R. Surendran, T. Sujaritha, C. Ganesh Babu   +4 more
semanticscholar   +1 more source

Real-World Evidence on Use of Ceftazidime-Avibactam in the Management of Gram-Negative Infections: A Retrospective Analysis

Cureus
There is limited real-world data from India examining the treatment characteristics, safety, and efficacy of ceftazidime-avibactam against Gram-negative organisms especially multidrug-resistant pathogens including carbapenem-resistant Enterobacterales ...
S. Todi, Prachee Sathe, R. V, Subramanian Swaminathan, Deepak Talwar, P. Prayag, Polati Vishnu Rao, Kirti Sabnis, Shweta Kamat, A. Mane, Harish Thanusubramanian   +10 more
semanticscholar   +1 more source

Impact of renal-adjusted ceftazidime/avibactam in patients with KPC-producing Klebsiella pneumoniae bloodstream infection: a retrospective cohort study

JAC-Antimicrobial Resistance
Background Bloodstream infections (BSIs) caused by KPC-producing Klebsiella pneumoniae (KPC-Kp) are still associated with high mortality, and the game-changing drug ceftazidime/avibactam has shown suboptimal pharmacokinetics in some clinical settings ...
A. Oliva, L. Volpicelli, A. Gigante, M. Di Nillo, S. Trapani, A. Viscido, F. Sacco, C. Mastroianni   +7 more
semanticscholar   +1 more source

Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance

mSystems
Klebsiella pneumoniae carbapenemases (KPCs) have evolved into over 245 distinct variants, with over one-third of variants exhibiting reduced susceptibility to ceftazidime-avibactam, while the underlying selection mechanisms remain elusive.
Jie Wei, Jinyu Huang, Chunhong Zou, Shimei Shen, Barry N. Kreiswirth, Ailong Huang, Shifeng Huang, Liang Chen, Deqiang Wang, Siqiang Niu   +9 more
doaj   +1 more source

Ceftazidime-avibactam induced renal disorders: past and present

Frontiers in Pharmacology
With the increasing prevalence of multidrug-resistant Gram-negative bacterial pathogens worldwide, antimicrobial resistance has become a significant public health concern. Ceftazidime-avibactam (CAZ-AVI) exhibited excellent in vitro activity against many
Yanrong Shi, Jichao Wu, Wei Mi, Xusheng Zhang, Xiuli Ren, Chengwu Shen, Cuicui Lu   +6 more
semanticscholar   +1 more source

Evolution of ceftazidime-avibactam and cefiderocol resistance in ST131-H30R1-Escherichia coli isolates with KPC-3 mutants and application of FTIR biotyping

Microbiology spectrum
Ceftazidime-avibactam and cefiderocol represent two of the few alternatives for infections by KPC-producing Enterobacterales. We reported the emergence of resistance to both ceftazidime-avibactam and cefiderocol in a KPC-producing ST131-Escherichia coli (
Juan Antonio Castillo-Polo, M. Hernández-García, Ainhize Maruri-Aransolo, Carmen de la Vega, P. Ruiz-Garbajosa, R. Cantón   +5 more
semanticscholar   +1 more source